Trials / Completed
CompletedNCT00479648
A Phase 2 Study of Immunogenicity, Safety and Tolerability of CSL412 in Elderly Participants
A Phase II, Double-Blind, Randomised, Controlled, Multi-Centre Study to Evaluate the Immunogenicity, Safety and Tolerability of Three Formulations of CSL412 in Adults (≥ 18 to ≤ 45 Years) and Older Adults (≥ 60 Years)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 612 (actual)
- Sponsor
- Seqirus · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
Current influenza vaccines have a reduced efficacy in the elderly. This study will investigate the immunogenicity, safety and tolerability of an adjuvanted influenza vaccine in elderly participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CSL412 | |
| BIOLOGICAL | Inactivated trivalent influenza vaccine |
Timeline
- Start date
- 2007-05-01
- Primary completion
- 2007-08-01
- Completion
- 2007-08-01
- First posted
- 2007-05-28
- Last updated
- 2016-07-19
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00479648. Inclusion in this directory is not an endorsement.